1In April, 1988, Shenzhen Municipal Government approved the establishment of Shenzhen Bioengineering Company.
1April 1992, the Ministry of Health and the Shenzhen Municipal Government approved the establishment of Shenzhen Kangtai Biological Products Co., Ltd. to undertake the project of introducing recombinant (yeast) hepatitis B vaccine.
From June, 5438 to February, 2002, the Ministry of Finance and Shenzhen Municipal Government approved Kangtai Bio, with China Development and Investment Company, Shanghai Huarui Investment Co., Ltd., Beijing Gaoxin Venture Capital Co., Ltd., Hunan Gaoxin Venture Capital Co., Ltd. and Shanghai Jiaotong University Only Co., Ltd. as sponsors, and the whole company was transformed into a joint stock company, and entered the listing counseling period.
In September, 2005, Kangtai Bio officially submitted the listing counseling acceptance materials to Shenzhen Supervision Bureau of China Securities Regulatory Commission, and passed the examination, thus completing the listing counseling of the company.
In September 2008, Kangtai Bio successfully reorganized its strategy, adding three new shareholders, including Shenzhen Ruiyuanda Investment Co., Ltd., and increasing its registered capital to RMB 357 million.
In 2008, Kangtai Bio carried out strategic capital reorganization with a registered capital of 357 million RMB.